TOPIC
Timely research progression and assay development for COVID-19 is crucial and at the same time hindered by proper social distancing. Open, automated platforms like Simple Western and SimplePlex with the 48-Digoxigenin cartridge allow researchers to make much needed progress quickly by enabling immediate use of proteins and antibodies as they become available while at the same time minimizing time to results and time in the lab.
In this webinar we highlight assay development strategies, discuss which assays in the COVID-19 space should be used for which questions and showcase new SARS-CoV-2 data on basic research applications as well as serological assays for COVID-19.
SPEAKERS
 |
|
Annegret Boge, Ph.D.
Senior Director, Western BU Leader
Bio-Techne
|
|
Annegret obtained her MSc in Chemistry at the WWU, Muenster and her PhD in Analytical Biochemistry from the Technical University of Munich (TUM), Germany. She completed her PostDoc at Stanford.
In 2008 Annegret joined ProteinSimple, a Bio-Techne brand, in the R&D team developing reagents, methods and technologies for protein analysis. Annegret is now the Western Business Unit leader in the BioTechne-Analytical Solutions Division responsible for Single-Cell Western, Simple Western and Imaging product lines.
|
|
 |
|
Kelly Gardner, Ph.D.
Director, Product Management & Business Dev.
Bio-Techne
|
|
Kelly obtained her Ph.D. in bioengineering from UC Berkeley, an MBA equivalent (MPhil) from Cambridge University as a Gates Scholar and a BS in Biomedical Engineering and Mechanical Engineering from Yale University.
Kelly is the former CEO & co-founder of Zephyrus Biosciences, the life science start-up company that developed the Single-Cell Western product line, Milo. For her work leading Zephyrus from incorporation through to acquisition by Bio-Techne, she was named one of the top 35 entrepreneurs under 35 globally by the MIT Tech Review
|
